Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide
暂无分享，去创建一个
[1] V. Backer,et al. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 , 2021, The Lancet Regional Health - Europe.
[2] E. Phillips,et al. Maintaining Safety with SARS-CoV-2 Vaccines , 2020, The New England journal of medicine.
[3] John P. Moore,et al. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds. , 2020, Journal of virology.
[4] A. Iwasaki,et al. The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.
[5] W. Koff,et al. Covid-19 and Immunity in Aging Populations - A New Research Agenda. , 2020, The New England journal of medicine.
[6] R. Schreiber,et al. Niclosamide repurposed for the treatment of inflammatory airway disease. , 2019, JCI insight.
[7] J. Ousingsawat,et al. TMEM16A in Cystic Fibrosis: Activating or Inhibiting? , 2019, Front. Pharmacol..
[8] Dirk E. Smith,et al. Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways , 2018, bioRxiv.
[9] Wooseong Kim,et al. Repurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus aureus , 2015, PloS one.
[10] R. Schwendener,et al. Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral Effects , 2012, PLoS pathogens.